US Senate steps in on FDA pre-exemption proposal
This article was originally published in Clinica
Executive Summary
Critics continue to lambast the controversial FDA proposal which would limit companies' ability to cite agency approval of a product or clinical trials as a defence against product liability lawsuits at state level.